JPMorgan lowered the firm’s price target on Pfizer to $36 from $39 and keeps a Neutral rating on the shares ahead of the Q3 report. The firm is below Street estimates on lower COVID numbers. And on Pfizer’s non-COVID business trends are mixed, the analyst tells investors in a research note. The firm continue to expects the shares to be range-bound and sees fairly limited downside from current levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE: